The migraine medication galcanezumab might protect against adverse CV events in patients taking the drug for episodic headaches, according to research presented at the American Academy of Neurology’s 2019 meeting in Philadelphia.

Vivimed Life Sciences on May 3 announced a voluntary recall of 19 lots of losartan potassium tablets, making it the third company in two weeks to issue a recall of the blood pressure (BP) drug.

A Harvard cardiologist and his team have developed an experimental genetic test for predicting obesity, NPR reports.

Long-term exposure to low doses of ionizing radiation raises a person’s risk for developing high blood pressure, according to a Hypertension study of more than 22,000 nuclear facility workers in Russia.

A study of more than 750 kids who were followed into their thirties has linked oral infections in childhood to CVD later in life—particularly subclinical carotid atherosclerosis.

Coronary artery bypass grafting (CABG) surgery beat out stent placement with percutaneous coronary intervention (PCI) in a recent study of patients with multivessel coronary artery disease. Patients saw lower risks of death, hospital readmission and revascularization with the former procedure.

SCAI has diversified its planning committees and expanded the focus on live cases for its 2019 scientific sessions, says Program Chair Sunil Rao, MD.

After a successful safety and feasibility trial run, the FDA granted approval April 26 to the STEMI DTU (ST-Elevation Myocardial Infarction Door-to-Unloading) study, which will examine whether unloading the left ventricle prior to reperfusion can reduce myocardial damage and lead to fewer CV complications in STEMI patients.